Monitoring methods, considerations, and statement of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) Ethical Review Committee.
The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) was terminated prematurely when an independent Ethical Review Committee concluded, on the basis of interim analyses, that continuation would not be advisable on either ethical or scientific grounds. Among 124 patients treated with enalapril and 120 randomized to placebo, 6-month mortality rates were 27 and 48%, respectively. The 2 groups were found to be well balanced with regard to baseline clinical characteristics, and a consistent treatment effect was evident among subgroups. Furthermore, the difference favoring enalapril was found to have been present since the beginning of the study and was consistent over time. Based on these findings, the study was halted on December 14, 1986.
Lubsen
J
J
Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.
D002908:Chronic Disease; D004656:Enalapril / Q000627:therapeutic use*; D004992:Ethics, Medical; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D008722:Methods; D012537:Scandinavian and Nordic Countries
D004656:Enalapril